- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07939529
People With Active Viremia Treated With Lenacapavir and Long-Acting Cabotegravir for Effectiveness (PALACE)
This pilot, single-arm, open-label study conducted in the United States will evaluate the efficacy, safety, tolerability, and pharmacokinetics of long-acting lenacapavir plus cabotegravir (LA LEN+CAB) in people with HIV-1 viremia who have a history of non-adherence and confirmed or suspected rilpivirine (RPV) resistance. Participants will be on study for up to 108 weeks.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- La phase 1
Contacts et emplacements
Lieux d'étude
-
-
Alabama
-
Birmingham, Alabama, États-Unis, 35222
- Alabama (Site ID: 31788)
-
Contact:
- Heather Logan
- Numéro de téléphone: 205-934-6774
- E-mail: heatherlogan@uabmc.edu
-
-
California
-
Los Angeles, California, États-Unis, 90035
- University of California, Los Angeles CARE Center (Site ID: 601)
-
Contact:
- Aleen Khodabakhshian
- Numéro de téléphone: 310-557-3798
- E-mail: akhodabakhshian@mednet.ucla.edu
-
San Diego, California, États-Unis, 92103
- UCSD Antiviral Research Center (Site ID: 701)
-
Contact:
- Dawn Rosenblum
- Numéro de téléphone: 619-543-8080
- E-mail: drosenblum@health.ucsd.edu
-
San Francisco, California, États-Unis, 94110
- University of California, San Francisco (Site ID: 801)
-
Contact:
- Jay Dwyer
- Numéro de téléphone: 415-502-5748
- E-mail: jay.dwyer@ucsf.edu
-
Torrance, California, États-Unis, 90502-2052
- Harbor University of California Los Angeles Center (Site ID: 603)
-
Contact:
- Mario Guerrero
- Numéro de téléphone: 323-457-1459
- E-mail: mguerrero@lundquist.org
-
-
Colorado
-
Aurora, Colorado, États-Unis, 80045
- University of Colorado Hospital (Site ID: 6101)
-
Contact:
- Nicola Haakonsen
- Numéro de téléphone: 303-724-5931
- E-mail: nicola.haakonsen@cuanschutz.edu
-
-
District of Columbia
-
Washington D.C., District of Columbia, États-Unis, 20032
- Whitman-Walker Institute, Inc. (Site ID: 21791)
-
Contact:
- Avery Wimpelberg
- Numéro de téléphone: 202-797-3589
- E-mail: awimpelberg@whitman-walker.org
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60611
- Northwestern University (Site ID: 2701)
-
Contact:
- Sherryl L Wolfe
- Numéro de téléphone: 312-695-4997
- E-mail: s-wolfe@northwestern.edu
-
-
Maryland
-
Baltimore, Maryland, États-Unis, 21287
- Johns Hopkins University (Site ID: 201)
-
Contact:
- Rebecca L Becker
- Numéro de téléphone: 410-614-4036
- E-mail: rbecke22@jhmi.edu
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02114
- Massachusetts General Hospital (Site ID: 101)
-
Contact:
- Amy Sbrolla
- Numéro de téléphone: 617-726-5598
- E-mail: asbrolla@mgh.harvard.edu
-
Boston, Massachusetts, États-Unis, 02115
- Brigham and Women's Hospital Therapeutics (BWH TCRS) (Site ID: 107)
-
Contact:
- Hannah Jordan
- Numéro de téléphone: 617-732-4785
- E-mail: hcjordan@bwh.harvard.edu
-
-
New Jersey
-
Newark, New Jersey, États-Unis, 07103
- New Jersey Medical School Clinical Research Center (Site ID: 31786)
-
Contact:
- Christie Lyn Costanza
- Numéro de téléphone: 972-972-9069
- E-mail: costancl@njms.rutgers.edu
-
-
New York
-
New York, New York, États-Unis, 10010
- Weill Cornell Chelsea (Site ID: 7804)
-
Contact:
- Mauricio Vergara
- Numéro de téléphone: 212-746-7204
- E-mail: mav9177@med.cornell.edu
-
New York, New York, États-Unis, 10010
- Weill Cornell Uptown (Site ID: 7803)
-
Contact:
- Keisha Ballentine-Cargill
- Numéro de téléphone: 212-746-7804
- E-mail: keb4006@med.cornell.edu
-
New York, New York, États-Unis, 10032
- Columbia Physicians & Surgeons (P&S) (Site ID: 30329)
-
Contact:
- Brett T Gray
- Numéro de téléphone: 212-305-1570
- E-mail: bg2168@cumc.columbia.edu
-
-
North Carolina
-
Chapel Hill, North Carolina, États-Unis, 27599-7215
- Chapel Hill (Site ID: 3201)
-
Contact:
- Erin Elizabeth Hoffman
- Numéro de téléphone: 919-843-0720
- E-mail: erin_hoffman@med.unc.edu
-
Greensboro, North Carolina, États-Unis, 27401-1020
- Greensboro (Site ID: 3203)
-
Contact:
- Kelly Phillips
- Numéro de téléphone: 336-832-7297
- E-mail: kelly.phillips@conehealth.com
-
-
Ohio
-
Cincinnati, Ohio, États-Unis, 45267-0405
- Cincinnati Clinical Research Site (Site ID: 2401)
-
Contact:
- Michelle Saemann
- Numéro de téléphone: 513-584-2245
- E-mail: saemanmd@ucmail.uc.edu
-
Cleveland, Ohio, États-Unis, 44106
- Case Clinical Research Site (Site ID: 2501)
-
Contact:
- Julie Pasternak
- Numéro de téléphone: 216-844-2738
- E-mail: pasternak.julie@clevelandactu.org
-
Columbus, Ohio, États-Unis, 43210
- Ohio State University (Site ID: 2301)
-
Contact:
- Lindsay Summers
- Numéro de téléphone: 614-293-8529
- E-mail: lindsay.summers@osumc.edu
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, États-Unis, 15213
- University of Pittsburgh (Site ID: 1001)
-
Contact:
- Stacey Edick
- Numéro de téléphone: 412-383-1748
- E-mail: edicksm2@upmc.edu
-
-
Tennessee
-
Nashville, Tennessee, États-Unis, 37204
- Vanderbilt Therapeutics (VT) (Site ID: 3652)
-
Contact:
- Beverly Woodward
- Numéro de téléphone: 615-936-8516
- E-mail: beverly.o.woodward@vumc.org
-
-
Texas
-
Houston, Texas, États-Unis, 77030
- Houston Advancing Research Team (Site ID: 31473)
-
Contact:
- Maria Laura Martinez
- Numéro de téléphone: 713-500-6718
- E-mail: maria.l.martinez@uth.tmc.edu
-
-
Washington
-
Seattle, Washington, États-Unis, 98104
- University of Washington Positive Research (Site ID: 1401)
-
Contact:
- Allysson Angeldekao
- Numéro de téléphone: 503-715-7324
- E-mail: allysson@uw.edu
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
-
Documented HIV-1 infection
-
Prior antiretroviral therapy (ART) experience, including having first been prescribed ART at least 24 weeks prior to enrollment and self-report of prior oral ART use
-
HIV-1 RNA >1000 copies/mL within 60 days prior to study entry
-
Evidence of non-adherence to ART, including virologic failure, poor virologic response, or loss to clinical follow-up with ART non-use/non-adherence
-
At least one reason why NNRTI-based ART is clinically inappropriate, including documented or suspected rilpivirine resistance or prior rilpivirine intolerance
-
Adequate laboratory parameters within 60 days prior to study entry:
- Absolute neutrophil count >600/mm3
- Hemoglobin ≥7.0 g/dL
- Platelet count >50,000/μL
- AST and ALT ≤3 × upper limit of normal
- Estimated glomerular filtration rate >15 mL/min/1.73 m²
-
For participants of childbearing potential, negative pregnancy test at screening and within 24 hours prior to study entry
-
Ability and willingness to provide informed consent
-
Connected to a medical clinic with access to HIV care and antiretroviral therapy
Exclusion Criteria:
- Documented integrase strand transfer inhibitor (INSTI) resistance-associated mutations that may compromise cabotegravir activity
- Active hepatitis B infection, defined as positive hepatitis B surface antigen or detectable hepatitis B virus DNA
- Child-Pugh Class C cirrhosis
- No suitable injection site for cabotegravir administration due to implants, tattoos, or skin conditions interfering with injection site assessment
- Prior use of lenacapavir
- Receipt of HIV immunotherapeutic vaccines or HIV monoclonal antibodies within 6 months prior to study entry
- Serious medical or psychiatric condition
- Use of prohibited concomitant medications with lenacapavir or cabotegravir within 30 days prior to study entry
- Current pregnancy or breastfeeding
- Known allergy, hypersensitivity, or intolerance to cabotegravir, lenacapavir, or formulation components
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Long-Acting Lenacapavir Plus Long-Acting Cabotegravir
|
Long-acting subcutaneous lenacapavir administered every 24 weeks with oral loading doses at treatment initiation. Long-acting intramuscular cabotegravir administered every 8 weeks following initiation doses. Oral antiretroviral therapy provided as bridge therapy during interruptions or delays in long-acting treatment. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
Proportion of participants achieving and maintaining viral suppression (no confirmed virologic failure) while receiving long-acting lenacapavir plus cabotegravir
Délai: Baseline through Week 48
|
Baseline through Week 48
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Proportion of participants with HIV-1 RNA <50 copies/mL by FDA Snapshot analysis
Délai: Week 48
|
Week 48
|
|
|
Proportion of participants with HIV-1 RNA <200 copies/mL by FDA Snapshot analysis
Délai: Week 48
|
Week 48
|
|
|
Proportion of participants with regimen success, defined as remaining on long-acting lenacapavir plus cabotegravir without confirmed virologic failure
Délai: Week 48
|
Week 48
|
|
|
Proportion of participants with Grade 3 or higher adverse events related to long-acting lenacapavir plus cabotegravir
Délai: Baseline through Week 96
|
Baseline through Week 96
|
|
|
Proportion of participants discontinuing long-acting lenacapavir plus cabotegravir due to adverse events or intolerance
Délai: Baseline through Week 96
|
Baseline through Week 96
|
|
|
Proportion of participants achieving and maintaining viral suppression without confirmed virologic failure on long-acting lenacapavir plus cabotegravir
Délai: Baseline through Week 96
|
Baseline through Week 96
|
|
|
Proportion of participants with HIV-1 RNA <50 copies/mL by FDA Snapshot analysis
Délai: Week 96
|
Week 96
|
|
|
Proportion of participants with HIV-1 RNA <200 copies/mL by FDA Snapshot analysis
Délai: Week 96
|
Week 96
|
|
|
Proportion of participants with regimen success, defined as remaining on long-acting lenacapavir plus cabotegravir without confirmed virologic failure
Délai: Week 96
|
Week 96
|
|
|
Percentage of on-time long-acting injections
Délai: Through Week 48 and through Week 96
|
Through Week 48 and through Week 96
|
|
|
Proportion of participants discontinuing long-acting lenacapavir plus cabotegravir
Délai: Baseline through Week 48 and through Week 96
|
Baseline through Week 48 and through Week 96
|
|
|
Plasma trough concentrations of lenacapavir and cabotegravir
Délai: Through Week 48 and through Week 96
|
Through Week 48 and through Week 96
|
|
|
Change in CD4 cell count from baseline
Délai: Week 48 and Week 96
|
Week 48 and Week 96
|
|
|
Participant-reported treatment satisfaction
Délai: Week 48 and Week 96
|
HIV Treatment Satisfaction Questionnaire assesses participant satisfaction with the long-acting treatment. |
Week 48 and Week 96
|
|
Change in quality-of-life scores from baseline
Délai: Week 48 and Week 96
|
Quality of life will be assessed using the Veterans Rand 12-item Health Survey (VR-12). Scores range from 0 to 100, with higher scores indicating better health-related quality of life. |
Week 48 and Week 96
|
|
Change in Patient Health Questionnaire-9 (PHQ-9) scores from baseline
Délai: Week 48 and Week 96
|
Symptoms will be assessed using the Patient Health Questionnaire-9 (PHQ-9). Scores range from 0 to 27, with higher scores indicating more severe depressive symptoms. |
Week 48 and Week 96
|
|
Proportion of participants achieving and maintaining viral suppression without confirmed virologic failure among participants not requiring oral bridge therapy
Délai: Baseline through Week 48
|
Baseline through Week 48
|
|
|
Proportion of participants without oral bridge therapy with HIV-1 RNA <50 copies/mL by FDA Snapshot analysis
Délai: Week 48
|
Week 48
|
|
|
Proportion of participants without oral bridge therapy with HIV-1 RNA <200 copies/mL by FDA Snapshot analysis
Délai: Week 48
|
Week 48
|
|
|
Proportion of participants without oral bridge therapy with regimen success, defined as remaining on long-acting lenacapavir plus cabotegravir without confirmed virologic failure
Délai: Week 48
|
Week 48
|
Collaborateurs et enquêteurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- A5431
- 39159 (Autre identifiant: DAIDS-ES ID)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Individual participant data that underlie results in the publication after deidentification
Délai de partage IPD
Beginning 3 months following publication and available throughout period of funding of the Advancing Clinical Therapeutics Globally (ACTG) by NIH
Critères d'accès au partage IPD
With whom? Researchers who provide a methodologically sound proposal for use of the data that is approved by the ACTG.
For what types of analyses? To achieve aims in the proposal approved by the ACTG.
By what mechanism will data be made available? Researchers may submit a request for access to data using the ACTG "Data Request" form at: https://actgnetwork.org/submit-a-proposal/. Researchers of approved proposals will need to sign an ACTG Data Use Agreement before receiving the data
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .